DDInter448 DDInter1376
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Crizotinib {u} (Compound) treats {v} (Disease) lung cancer
Crizotinib {u} (Compound) binds {v} (Gene) MET
Crizotinib {u} (Compound) upregulates {v} (Gene) COL11A1
Crizotinib {u} (Compound) is included by {v} (Pharmacologic Class) Organic Cation Transporter 2 Inhibitors
Crizotinib {u} (Compound) downregulates {v} (Gene) WDR77
Crizotinib {u} (Compound) causes {v} (Side Effect) Dizziness postural
Crizotinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Crizotinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fedratinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enfortumab vedotin
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gefitinib
Crizotinib (Compound) treats lung cancer (Disease)
Crizotinib (Compound) binds MET (Gene)
Crizotinib (Compound) upregulates COL11A1 (Gene)
Crizotinib (Compound) is included by Organic Cation Transporter 2 Inhibitors (Pharmacologic Class)
Crizotinib (Compound) downregulates WDR77 (Gene)
Crizotinib (Compound) causes Dizziness postural (Side Effect)
Crizotinib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Crizotinib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib